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Background:  An analysis  of the  value  and  limits  of  non-robotic  transoral  oropharyngectomy  for  local
control  of  T1-2  squamous  cell  carcinoma  of  the  tonsillar  fossa.
Methods:  A  retrospective  series  of  111  T1 and 133  T2  (N0:  129;  N1: 52; N2:  53; N3:  10).  Induction
chemotherapy  and  postoperative  radiation  therapy  were  used  in  63.5%  and  29.5%  of cases,  respectively.
Actuarial  analysis  of  local  failure,  impact  of  various  variables  upon  local  failure  and  consequences  of  local
failure upon  other  oncological  events  and  survival  are  documented.
Results:  The  5-year  actuarial  local  failure  estimate  was  10.4%  and  14.2%  for  T1 and  T2 tumors,  respectively.
The  5-year  actuarial  local  failure  estimate  was  signiﬁcantly  reduced  when  resection  margins  were  safe
or yielded  dysplasia  (P =  0.008)  and  when  induction  chemotherapy  achieved  complete  histologic  regres-
sion  (P  =  0.013).  Salvage  treatment  achieved  a 97.2%  and  93.2%  overall  local  control  rate  in  T1  and  T2
tumors,  respectively.  The  5-year  actuarial  nodal  failure  estimate  was  35.1%  in  patients  with  local  failure
versus  10.8%  without  (P =  0.0001).  The  5-year  actuarial  metachronous  second  primary  estimate  was  7%  in
patients with  local  failure  versus  33.2%  without  (P =  0.016).  The  impact  of  local  failure  on  survival  (5-year
actuarial  survival  estimate:  67.3%  without  and  46.4%  with  local  failure)  was  not  signiﬁcant.
Conclusion:  In  T1-2  squamous  cell  carcinoma  of  the tonsillar  fossa,  non-robotic  transoral  oropharyn-
gectomy  appeared  to be highly  effective  in  terms  of  local  control.  The  high  incidence  of  head  and  neck
metachronous  second  primaries  further  advocates  the  use  of this  treatment  option  in order  to  reserve
radiation  therapy  to  such cases.
©  2015  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
In recent years, various ﬁndings modiﬁed the management of
1-2 squamous cell carcinoma of the tonsillar fossa. The spread of
uman papilloma virus (HPV) threatens a sharp increase in inci-
ence in coming decades in younger patients with better general
ealth status and is thought to favor radiosensitivity [1–3]. Sev-
ral studies, however, have also highlighted the high rate of severe
unctional complications associated with radiation therapy as a pri-
ary therapeutic attitude [4–6]. Furthermore, several teams have
escribed mandible-sparing transoral surgery as an attractive alter-
ative [7–12].These ﬁndings inspired the present retrospective study, seeking
o determine the value and limits of non-robotic transoral oropha-
yngectomy for local control of T1-2 squamous cell carcinoma of the
∗ Corresponding author.
E-mail address: ollivier.laccourreye@egp.aphp.fr (O. Laccourreye).
http://dx.doi.org/10.1016/j.anorl.2015.03.010
879-7296/© 2015 Elsevier Masson SAS. All rights reserved.tonsillar fossa. In a cohort of 244 consecutively operated patients,
the study focused on actuarial analysis of local failure, risk factors,
and impact on nodal failure, distant metastasis, metachronous sec-
ond primaries and survival. Results are discussed in the light of
the literature (PubMed analysis) to compare the value and limits of
non-robotic transoral oropharyngectomy versus radiation therapy,
which is the classic conservative treatment option.
2. Material and methods
Two  hundred and forty-four patients (50 female and 194 male
with a median age of 58 years – range: 35–83 years) with differ-
entiated invasive squamous cell carcinoma of the tonsillar fossa
(anterior pillar, tonsil, posterior pillar) staged as T1-2 (111 T1 and
133 T2) N0-3 (129 N0, 52 N1, 53 N2 a or b, and 10 N3) according to
the International Union Against Cancer classiﬁcation [13], consec-
utively operated on by non-robotic transoral oropharyngectomy
in the Otorhinolaryngology Head & Neck Surgery departments of
the Laënnec/Georges-Pompidou European Hospital (Paris, France)
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Table 1
General data.
n (%)
Smoking 202 (82.7)
Alcohola > 1 liter wine/day 90 (36.8)
Comorbidityb (Charlson scale[14])
0  103 (42.2)
1–2 91 (37.2)
3–4 40 (11.6)
≥ 5 10 (4)
Oncologic history 56 (22.9)
Non H&N cancer 10 (4)
3  colon, 2 breast, 1 uterus, 1
kidney, 1 prostate, 1 lung, 1
hematologic
H&N cancer 46 (18.8)
14  endolarynx, 12 oropharynx (inc.
2 contralateral tonsils), 10
hypopharynx-epilarynx, 7 oral
cavity, 2 lymphomas, 1 adenopathy
from unknown primary.
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Table 2
Tumor site of origin and extension.
n (%)
Site of origin
Tonsil 139 (56.9)
Anterior pillar 88 (36)
Posterior pillar 17 (6.9)
Extension
Tonsil 162 (66.3)
Anterior pillar 136 (55.7)
Posterior pillar 59 (24.1)
Ipsilateral soft palate 46 (18.8)
Junction anterior pillar-mobile tongue 45 (18.4)
Infratonsillar region 37 (15.1)
Glossotonsillar fold 13 (5.3)
Uvula 10 (4)
Contralateral soft palate 9 (3.6)
Intermaxillary commissure 9 (3.6)
Posterior ﬂoor of the mouth 6 (2.4)
Posterior pharyngeal wall 3 (1.2)
Ipsilateral hard palate 2 (0.8)
Mobile tongue 2 (0.8)
Ipsilateral vallecula 2 (0.8)a 10 missing data.
b 1 missing datum.
etween 1978 and 2008, were included in the current retrospective
tudy. Exclusion criteria comprised:
cancers other than invasive squamous cell carcinoma;
invasive squamous cell carcinoma originating from an adjacent
site with extension to the tonsillar fossa;
T1-2 invasive squamous cell carcinoma operated on with robotic
assistance;
patients operated on with an associated ipsilateral lateral pharyn-
gotomy, mandibular sectioning or mandibular resection;
recurrent invasive squamous cell carcinoma following radiation
therapy or radiochemotherapy and;
patients with synchronous second primary, refusing surgery
and/or with contraindications for general anesthesia.
Table 1 details smoking status and alcohol abuse, comorbidity
n the Charlson scale [14] and oncological history. Among the 43
atients previously treated for a prior squamous cell carcinoma:
3 partial supraglottic partial laryngectomies, 5 supracricoid par-
ial laryngectomies, 3 contralateral transoral oropharyngectomies
nd 7 total laryngectomies were performed with radiation therapy
median dose, 55 Gray; range, 45–75 Gray) to the oropharynx being
sed in 13 cases.
Table 2 details the presumed anatomic site of origin of the
nvasive squamous cell carcinoma and the anatomic sites listed as
nvaded on extension assessment. There were no cases of involve-
ent of the base of the tongue, torus tubarius and epilarynx.
he tongue motion was within normal limits. There was  no tris-
us  and no deep ﬁxation of the tonsil. Preoperative imaging
ound no involvement of the mandible, hard palate, parapharyngeal
paces and/or styloglossus, hyoglossus, mylohyoid and/or ipsilat-
ral medial pterygoid muscles.
Ahead of transoral oropharyngectomy, diagnostic tonsillec-
omy, diagnostic adenectomy and platinum-based induction
hemotherapy were performed in respectively 5.7% (14/244), 4.1%
10/244) and 63.5% (155/244) of cases. Induction chemotherapy
as performed for advanced tumoral stage (III or IV) in 60.6%
94/155) of cases, or to arrest evolution ahead of surgery in the
emaining 39.4% (61/155) of cases staged I or II. Due to life-
hreatening toxicity, induction chemotherapy was interrupted in
.5% (3/155) of cases.
Transoral oropharyngectomy was performed by electrocautery
bowie knife) without robotic assistance or laser, and was either
ateral oropharyngectomy according to the technique initiallyCheek mucosa 1 (0.4)
Pelvilingual fold 1 (0.4)
described by Huet [15,16] (213 patients) or an eletrocautery
resection (31 patients). Ipsilateral level II–IV neck dissection was
associated in 75% (183/244) of cases, further associated to ipsilat-
eral level I and contralateral level II–IV dissection in respectively
6.5% (16/244) and 2% (5/244) of cases. In 61 N0 patients, no ipsilat-
eral neck dissection was associated, either because it had already
been performed due to the management of a prior cancer origi-
nating from the larynx or pharynx (30 cases) or because of patient
refusal and/or comorbidity (31 cases).
Pathologic examination of the specimen noted safe margins
(including millimeter-level margins), margins in dysplasia and pos-
itive margins in respectively 91.5% (223/244), 2% (5/244) and 6.5%
(16/244) of cases. Complete histologic regression (no tumor cells
in the specimen) and moderate to severe dysplasia were noted in
respectively 35.4% (55/155) and 10.9% (17/155) of patients follow-
ing induction chemotherapy. Postoperative radiation therapy was
performed in 29.5% (72/244) of cases. Mean dosage delivered to the
tonsillar fossa was  60 Gray (range: 40–75 Gray).
All patients, except for 6 who were lost to follow-up in postoper-
ative months 22, 48, 49, 53, 58 and 59 respectively, were followed
up for at least 5 years or until death. The Kaplan-Meier actuarial
life table method [17] and log rank test were used to assess local
failure and its relation to possible risk factors (gender, history of
diagnostic tonsillectomy, history of treatment for oropharyngola-
ryngeal cancer, oropharyngeal radiation therapy for other cancer, T
stage, tumor site of origin, affected sites, induction chemotherapy,
resection margins, complete histologic regression following induc-
tion chemotherapy and postoperative radiation therapy) and to
nodal failure, distant metastasis, metachronous second primaries
(other than basal cell carcinoma and deﬁned as any cancer anatomi-
cally distinct from the primary lesion) and survival. The signiﬁcance
threshold was  set at P < 0.05.
3. Results
3.1. Local failure
Twenty-eight local failures occurred, resulting in a 5-year actu-
arial local failure estimate of 10.2% for T1 and 14.2% for T2 tumor,
with no signiﬁcant difference (Table 3). There was only 1 case of
local failure diagnosed later than 5 years postoperatively (month
68).
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Table  3
Actuarial analysis (Kaplan-Meier method [17] with log rank test – P-values shown)
on  study variable impact on actuarial rate of 5-year local failure.
Study variables Local failure P-value
Gender (M/F) 0.34
Tumor origin (tonsil, anterior or posterior
pillar)
0.90
Sites involveda
Tonsil (yes/no) 0.88
Anterior pillar (yes/no) 0.15
Posterior pillar (yes/no) 0.10
Ipsilateral soft palate (yes/no) 0.97
Junction anterior pillar-tongue (yes/no) 0.96
Infratonsillar region (yes/no) 0.32
Glossotonsillar fold (yes/no) 0.49
Uvula (yes/no) 0.97
Intermaxillary commissure (yes/no) 0.19
T stage (T1/T2) 0.38
History of treated oropharyngolaryngeal
squamous cell carcinoma (yes/no)
0.35
History of oropharyngeal radiation therapy
(yes/no)
0.79
Diagnostic tonsillectomy (yes/no) 0.53
Induction chemotherapy (yes/no) 0.49
Complete histologic regression after induction
chemotherapy (yes/no)
0.013
Positive resection margins (yes/no) 0.008
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Fig. 1. Actuarial curves for local failure (Kaplan-Meier life table method [17] with
log rank test) according to: (a) resection margin status, (b) complete histologic
frequent than local failure, nodal failure and distant metastasis.
Table 4
Etiology of the 147 cases of death.
Cause of death n (%)
Treatment-related (3 during 1st postoperative
month and 1 following postoperative
radiation therapy)
4 (2.8)
Unknown 7 (4.7)Postoperative radiation therapy (yes/no) 0.99
a No statistical analysis of sites with < 3% involvement.
On univariate analysis (Table 3), the 5-year actuarial local failure
stimate increased signiﬁcantly according to 2 variables: the mar-
in status and the achievement of a complete histologic regression
fter induction chemotherapy. The 5-year actuarial local failure
stimate was 10.5% when the margins of resection were safe
r in dysplasia versus 27.1% when they were positive (Fig. 1 a;
 = 0.008). The 5-year actuarial local failure estimate was 4.1% when
 complete histologic regression after induction chemotherapy was
chieved versus 18% without (Fig. 1b; P = 0.013).
In the 16 patients with positive margins, the 5-year actuarial
ocal failure estimate was 30% in patients who had postoperative
adiation therapy and 33% in patients who did not (P = 0.7).
.2. Treatment of local failure
Local failure was salvaged in 57% (16/28) of cases. In 8 cases,
either surgery nor radiation therapy salvage was feasible and pal-
iative chemotherapy was initiated. In 16 of the other 20 cases, local
ontrol was achieved either by radiation therapy (n = 3), surgical
esection (n = 12), or surgical resection with postoperative radiation
herapy (n = 5). After salvage treatment, the overall local control
ate was 97.2% (108/111) in T1 and 93.2% (124/133) in T2 tumors.
.3. Consequences of local failure
Local failure had a signiﬁcant impact on nodal failure, with a 5-
ear actuarial nodal failure estimate of 10.8% without local failure
ersus 35.1% with (Fig. 2a; P = 0.0001). Local failure did not increase
he risk for distant metastasis, with a 5-year actuarial distant
etastasis estimate of 6.3% without local failure versus 4.8% with
P = 0.79). Local failure had a signiﬁcant impact on metachronous
econd primaries, with a 5-year actuarial metachronous second
rimary estimate of 7% with local failure versus 33.2% without
Fig. 2b; P = 0.016). Fig. 2b shows that metachronous second pri-
aries occurred well after the 5th postoperative year, with a
0-year actuarial estimate of 68.4% without local failure versus
7.6% with. And, 60.2% of metachronous second primaries (59/98)
ere of head and heck origin (29 oropharynx, including 5 in the
ontralateral tonsillar fossa, 13 hypopharynx and/or epilarynx, 9regression in the 155 patients who had induction chemotherapy.
oral cavity, 2 endolarynx, 2 lymph nodes from unknown primary, 1
nasopharynx, 1 trachea, 1 parotid and 1 cervical ﬁbrosarcoma) and
39.8% (39/97) non-head-and-neck (14 lung, 6 esophagus, 6 liver,
4 prostate, 3 colon, 2 breast, 1 bladder, 1 stomach, 1 cutaneous
melanoma and 1 bone).
One hundred and forty-seven patients died (Table 4), with a
5-year actuarial survival estimate of 70.7% in T1 and 62.2% in T2
tumors (P = 0.16). Local failure did not signiﬁcantly impact the 5-
year actuarial survival estimate (Fig. 2c; P = 0.38), which however
varied from 67.3% without local failure to 46.4% with. Table 4
underscores the main causes of death with metachronous second
primaries (40.1%) and intercurrent diseases (25.1%) being far moreLocal failure 12 (8.1)
Nodal failure and/or distant metastasis 28 (19)
Intercurrent disease 37 (25.1)
Metachronous second primary 59 (40.1)
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Table 5
Five-year actuarial local failure estimates following radiation therapy for T1 or T2
tonsillar squamous cell carcinoma in series with more than 40 patients.
Authors Date n Dose (Gray) % local failure
at 5 years
T1
Garett et al., [18] 1983 47 50–66 13
Mendenhall
et  al., [21]
2000 56 47–80. M:  65.6 17
Mendenhall
et  al., [6]
2006 75 47.2–81.7 12
T2
Garett et al., [18] 1983 161 50–66 32
Wong et al., [19] 1989 59 M:  67.8 19
Fein et al., [20] 1996 87 M:  76.8 21
Mendenhall
et  al., [21]
2000 150 47–80. M:  65.6 19
Charbonneau
et  al., [22]
2006 75 50–70. M:  68 26
Mendenhall 2006 191 47.2–81.7 26ig. 2. Actuarial curves (Kaplan-Meier life table method [17] with log rank test)
nalyzing impact of local failure on: (a) nodal failure, (b) metachronous second
rimaries, and (c) survival.
. Discussion
T1-2 squamous cell carcinoma of the tonsillar fossa is deﬁned, on
ll international classiﬁcations, as a tumor of maximal diameter not
xceeding 4 cm,  without involvement of the parapharyngeal spaces
r extrinsic muscles of the tongue or invasion of the mandible or
ard palate. In such cases, radiation therapy seems from the litera-
ure to be the most frequent mandible-sparing attitude worldwide,
ut is not without certain functional and oncological pitfalls. Func-
ionally, the rate of severe post-radiation complications (trismus,
adionecrosis, mandibular fracture, hemorrhage, carotid stenosis
ith risk of stroke, swallowing impairment requiring permanent
astrostomy and inducing pneumonia from inhalation) rangeset  al., [6]
N: number of patients; M:  median.
between 9% and 19% [4–6]. Oncologically, in series exceeding 40
patients [6,18–22], the 5-year actuarial local failure estimate ranges
between 12% and 17% in T1 and 19% and 32% in T2 tumor (Table 5).
Moreover, salvage surgery for local failure does not systematically
achieve local control, while inducing various complications and
non-negligible functional disability [6,22–24]. Bachar et al. [23],
in a retrospective study of 239 squamous cell carcinomas of the
tonsillar fossa treated by salvage surgery for post-radiation failure,
reported a 40% speciﬁc 5-year survival estimate. Furthermore, in
a retrospective study of a cohort of 1681 patients with oropharyn-
geal squamous cell carcinoma treated by radiation therapy, Zafereo
et al. [23] reported that 67% of patients who failed recurred after sal-
vage treatment, with a 3-year survival estimate no greater than 49%
while the rates of postoperative complication, swallowing impair-
ment and permanent tracheotomy were respectively 46%, 42% and
13% [24]. Finally, management of metachronous second primaries
of the head and neck is unreliable following radiation therapy, with
risk of radiation-induced cancer [25,26].
Since the initial publication by Pierre Charles Huet [15], sev-
eral teams [7–12] have addressed the role of conservative transoral
surgery in the treatment of invasive squamous cell carcinoma of
the tonsillar fossa. The present study follows these reports, adding
several interesting ﬁndings. The 5-year actuarial local failure esti-
mates of 10.2% for T1 and 14.2% for T2 tumors (Table 3) highlight the
beneﬁt of the transoral oropharyngectomy compared to radiation
therapy [6,18–22]. Moreover, the present results found no signiﬁ-
cant impact either of the site of origin or the various anatomic sites
invaded (Table 3) whereas radiation therapy achieves less effective
local control when squamous cell carcinoma of the tonsillar fossa
originates elsewhere than in the tonsil [27].
The importance of safe resection margins for local control of
squamous cell carcinoma of the tonsillar fossa is a well-established
notion [7,10,11]. In the present study, this variable signiﬁcantly
impacted the 5-year actuarial local failure estimate (Table 3), which
was 10.5% when the margins were safe or in dysplasia, versus 27.1%
in positive margins (Fig. 1 a; P = 0.008).
A particularity of the present series is its heterogeneity in terms
of site of origin, anatomic site invaded as depicted in Table 2,
comorbidities, use of a platinum-based induction chemotherapy
and postoperative radiation therapy (performed in respectively
63.5% and 29.5% of cases). This, along with the retrospective study
design, may be thought to weaken the present results. However,
to us, this heterogeneity is not without interest since it enabled
us to document that local failure was independent of the site of
origin within the tonsillar fossa and the anatomic sites invaded
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Table 3). Likewise, heterogeneity in comorbidity demonstrated
hat local control was unaffected by previous treatment of head
nd neck cancer (Table 3), making transoral oropharyngectomy a
aluable option in such cases. Heterogeneity in terms of induction
hemotherapy also demonstrated the lack of signiﬁcant impact on
he 5-year actuarial local control estimate (Table 3). Taken together
ith the risk of severe toxicity, which led to interruption of treat-
ent in 1.9% of cases, this suggests that induction chemotherapy
ould be viewed as an over-treatment that should not be associated
o transoral oropharyngectomy for T1-2 squamous cell carcinoma
f the tonsillar fossa. The present results, however, cast some
oubt on such an attitude: pathologic analysis found complete
istologic regression (absence of tumor cells in the specimen) in
5.4% of patients who had a platinum-based induction chemother-
py regimen. Moreover, in patients managed with the induction
hemotherapy, the 5-year actuarial local failure estimate varied
igniﬁcantly (Fig. 1b; P = 0.02) from 18% when complete histologic
egression was not achieved, to 4.1% in patients who achieved a
omplete histologic regression. Thus, the platinum-based induc-
ion chemotherapy regimen allowed, in more than a third of cases,
election of patients in whom the local control rate exceeded 95%,
hich, as can be seen from Table 5, is a rate that none of the previ-
us reports documenting 5-year actuarial local control estimates
ollowing radiation therapy in T1-2 squamous cell carcinoma of
he tonsillar fossa can match. To us, this strategy also affords time
or the team to determine, without urgency, the optimal deﬁnitive
reatment modality for the individual patient and tumor, while
especting the spirit of the Law of March 4, 2002 on patients’ rights
nd health-care quality [28]. Finally, it is noteworthy that the het-
rogeneity of the present series also allowed the suggestion that
he use of postoperative radiation therapy for positive margins did
ot reduce the risk of local failure: in the 15 patients with positive
argins, the 5-year actuarial local failure estimate was 30% with
ostoperative radiation therapy and 33% without (P = 0.7). Lastly,
t should also be noted that heterogeneity is common to all the
tudies published so far documenting the results of radiation ther-
py for T1-2 squamous cell carcinoma of the tonsillar fossa, since
ll these studies were retrospective and highly heterogeneous in
erms of radiation technique and dose (Table 5) [6,18–22].
The retrospective design of the present study precluded inves-
igation of the impact of HPV status on local control. However,
moking and alcohol consumption in excess of 1 liter of wine per
ay were found in respectively 82.7% and 36.8% of cases (Table 1),
uggesting that HPV status is of little relevance in terms of local con-
rol and/or resection margin status. This is in agreement with the
ecently expressed opinion of the Pennsylvania Otorhinolaryngol-
gy Head and Neck Surgery team [29], who demonstrated a lack of
mpact of HPV status on local control and survival in oropharyngeal
quamous cell carcinoma managed by transoral resection.
All these encouraging results should not lead to underestimat-
ng the seriousness of local failure, which, in the present series,
ould be salvaged in only 43% of cases and was associated with an
ncreased risk for nodal failure which showed a 5-year actuarial
stimate of 10.8% without local failure versus 35.1% with (Fig. 2a;
 = 0.0001). Even so, local failure did not signiﬁcantly affect survival
Fig. 2c; P = 0.38), probably due to two concomitant factors: the
mall size of the present series failed to give statistical power
o the difference in the 5-year actuarial survival estimate with
46.4%) and without (67.3%) local failure (Fig. 2c); and the high
ate (40.1%) of metachronous second primaries which represented
he main oncologic event and main cause of death (Table 5). And,
0.2% of these metachronous second primaries were of head and
eck origin and one half were oropharyngeal. The 20-year actuarial
ate was signiﬁcantly higher (Fig. 2b; P = 0.016) in case of local
ailure: 68.4% versus 27.6%. To us these last ﬁgures are a further
rgument in favor of transoral oropharyngectomy as primarylogy, Head and Neck diseases 132 (2015) 141–146 145
treatment in T1-2 squamous cell carcinoma of the tonsillar fossa,
while reserving the use of radiation therapy for the management
of head and neck metachronous second primaries.
5. Conclusion
The present 5-year actuarial data for local failure in a large
cohort conﬁrms the various reports published during the last 10
years [7–12] documenting the growing role of mandible-sparing
transoral surgery in T1-2 cancer of the tonsillar fossa. This conser-
vative surgical approach appeared to provide better local control
than does radiation therapy, while avoiding the associated severe
functional complications and allowing, in a large number of cases,
radiation therapy to be reserved for cases of metachronous sec-
ond primary of the head and neck. Given these ﬁndings and the
fact that HPV infection is associated with earlier onset of squamous
cell carcinoma of the tonsillar fossa, whereas the mean age of the
population is rising in France, this conservative surgical attitude
should in our opinion be systematically considered in the multidis-
ciplinary team meetings held before treatment. The present results
also highlight the usefulness of induction chemotherapy and the
limitations of postoperative radiation therapy, while providing a
large database for future pathology assessment of the interest of
robotic surgery for local control in T1-2 squamous cell carcinoma
of the tonsillar fossa.
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